jRCT2080221855UnknownPhase 3
Phase III Clinical Trial, long term treatment with TO-204 - Subcutaneous immunotherapy in patients with HDM-sensitized allergic rhinitis and asthma -
Trial Snapshot
- Phase
- Phase 3
- Enrollment
- 30
- Primary Endpoint
- -
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 5age old over to 65age old under (—)
- Sex
- All
Inclusion Criteria
- •Positive test in RAST(specific anti-HDM IgE >= Class 2)
- •Positive skin prick/scratch test against HDM allergen
Exclusion Criteria
- •Patients with clinical symptoms of perennial rhinitis or asthma caused by allergen other than HDM
- •Patients with severe asthma
- •Patients with severe systemic diseases (i.e., auto-immune disease, immunocomplex disease, immunodeficient disease)
Outcomes
Primary Outcomes
-
Safety
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Unknown
Phase 3
Phase III Clinical Trial, long term treatment with TO-204 - Subcutaneous immunotherapy in patients with HDM-sensitized allergic rhinitis and asthmaAllergic rhinitis or asthma sensitized to house dust miteJPRN-jRCT2080221855TORII PHARMACEUTICAL CO., LTD.30
Active, not recruiting
Not Applicable
A phase IIIB trial investigating 3-year treatment efficacy, tolerability and safety of Grazax in children aged 5-18 years with grass pollen induced rhinoconjunctivitis with/without controlled controlled asthma ( three consecutive pollen seasons treatment) - GT-23children from 5 to 18 years with grass pollen induced rhinoconjunctivitis with/without controlled asthmaMedDRA version: 9.1Level: LLTClassification code 10054928EUCTR2009-014923-22-ITALK-ABELLO`
Recruiting
Not Applicable
A phase 3 long-term treatment study to evaluate the safety and efficacy of AKP-022 in patients with uterine fibroids (LUNA2)jRCT2031240570ASKA Pharmaceutical Co., Ltd.350
Completed
Phase 3
Phase III Comparative Clinical Trial of Treatment Schedules for Oral UFT/LV Therapy as Postoperative Adjuvant Chemotherapy for Stage IIB/III Colorectal Cancercolorectal cancerJPRN-C000000245Japanese Foundation for Multidisciplinary Treatment of Cancer840
Active, not recruiting
Phase 1
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial CarcinomaAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2015-005731-41-IEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990